

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION

England & Wales · Charity number 1065026

Details

Other names BOPA

Status Registered

Legal form Other

Registered 1997-10-24

Register [View on the Charity Commission register](#)

Contact

Address GBH Ltd
Unit 7-8
Innovation Place
Douglas Drive
Godalming
Surrey

Phone 07885611995

Email dharmisha.chauhan@rmh.nhs.uk

Website www.bopawebsite.org

Activities

Objects: TO PROMOTE EXCELLENCE IN THE PHARMACEUTICAL CARE OF PATIENTS WITH CANCER, THROUGH EDUCATION, RESEARCH, INNOVATION AND COMMUNICATION BY FOSTERING AN ALLIANCE OF HOSPITAL, COMMUNITY AND ACADEMIC PHARMACISTS AND PHARMACY TECHNICIANS WITH THOSE WORKING IN THE PHARMACEUTICAL INDUSTRY AND IN OTHER HEALTHCARE PROFESSIONS.

Activities: BOPA promotes excellence in pharmaceutical care of British Cancer Patients

Classification

- **How:** Acts As An Umbrella Or Resource Body
- **What:** General Charitable Purposes
- **Who:** Other Defined Groups

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£143,086	£186,522	-	-
2024-03-31	£166,227	£257,186	-	-
2023-03-31	£161,533	£124,048	-	-
2022-03-31	£71,991	£71,596	-	-
2021-03-31	£71,725	£166,135	-	-

Trustees

Name	Role	Appointed
Joseph Williams		2020-02-09
Robert Duncombe		2017-12-01
emma foreman		2019-04-01

Accounts

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION

REPORT AND ACCOUNTS

FOR THE YEAR ENDED

31ST MARCH 2025

REGISTERED CHARITY NO. 1065026

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

CONTENTS

	<u>Page</u>
Trust Information	2
Independent Examiner's Report	3
Trustees Annual Report	5
Receipts and Payments Account	12
Statement of Assets and Liabilities	14

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

TRUST INFORMATION

Registered Charity No.	1065026
Trustees	Robert Duncombe Emma Foreman Joseph Williams
Treasurers	Anish Tailor Dharmisha Chauhan Shumi Tattersfield
Independent Examiner	Barry Fine
Address	c/o GBH Law, 7/8 Innovation Place Douglas Drive Godalming, Surrey GU7 1JX
Bankers	National Westminster Bank plc

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

I report to the trustees on my examination of the accounts for this charity for the year ended 31st March 2025, which are set out on pages 5 - 27.

Respective Responsibilities of the Trustees and Examiner

As the charity trustees of the charity, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

It is my responsibility to:

examine the accounts under section 145 of the Charities Act,

to follow the procedures laid down in the general directions given by the Charity Commission (under section 145(5)(b)) of the Charities Act, and

to state whether particular matters have come to my attention.

Basis of Independent Examiner's Report

My examination was carried out in accordance with the General Directions given by the Charity Commissioners. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)**

Independent Examiner's Statement

In connection with my examination, no matter has come to my attention:

- 1) which gives me reasonable cause to believe that in any material respect the requirements
 - a. to keep accounting records in accordance with Section 130 of the Charities Act, and
 - b. to prepare Accounts which accord with the accounting records and comply with the accounting requirements of the Charities Act.have not been met; or
- 2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the Accounts to be reached.

Name. B. Fine FCA
Address Parkgates
Bury New Road
Prestwich
Greater Manchester
M25 0JW

Dated 26 January 2026

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

BOPA is an unincorporated organisation governed by its constitution.

Charity Number 1065026

Administrative Details

Principal address: GBH Law, 7/8 Innovation Place, Douglas Drive, Godalming, Surrey, GU7 1JX

Member	Main Committee	Role within BOPA
Joseph Williams	Executive	Chair
Shereen Nabhani-Gebara	Executive	Vice Chair / EDI Co-Chair
Clayton Wong	Executive	Co-Secretary/ Digital Co-Chair / Website Manager
Michal Sladkowski	Executive	Co-Secretary / E&T Co-Chair / Podcast Lead
Dharmisha Chauhan	Executive	Co-Treasurer
Anish Tailor	Executive	Co-Treasurer
Shumi Tattersfield	Executive	Co-Treasurer
Mollie Bishop	Executive	Pharmacy Technician Rep
Rhiannon Walters-Davies	Executive	GAP Co-Chair – Interim Industry Rep
Alice Tew	Executive	Symposium / IO Co-Chair
Anita Carlier	Executive	Independent Sector Rep / Co Chair
Sofia Dutto	Executive	New to Oncology Rep
Diana Matthews	Executive	TBC

Structure

Members of the committee are elected for a three year term of office by the voting members through an electronic ballot. Each candidate provides a written statement in support of their application. These statements are electronically submitted to the members. The results of the election are announced at the Annual Symposium. Members can serve a maximum of two consecutive terms of office on the committee.

This committee then votes for the officers of Chair and Treasurer between themselves.

The association does not require any fundraising or grant-making activities. It is self-funding by members subscriptions, with additional sponsorship from the pharmaceutical industry for key projects such as e-Learning.

Decisions are made at the monthly committee meetings on behalf of the membership. The committee have several sub committees which feed back to the committee their decisions and ideas on behalf of the membership.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Sub committees:

1. Annual Symposium
2. Education and Training
3. Research
4. Community and Primary Care Pharmacy
5. Digital
6. Guidelines, Advocacy and Publications
7. Pharmacy Technician
8. Workforce and Capacity
9. Equity, Diversity, and Inclusion

Governance

Due to the nature of this charity no policies are in place to recruit and train trustees. Generally, those people elected by the members of the association are then responsible for the maintenance and safe handling of the Charity on behalf of the members.

Any decisions that require the membership to be involved in, such as national consultation documents, the document is placed on the BOPA website and emailed throughout the membership for comments to be received by the reference sub-committee who will then collate the response and return it.

The association works closely with the NHS England Cancer Area Team Pharmacists, and other relevant (oncology) pharmacy groups.

Objectives

The stated aim of BOPA is to promote excellence in the pharmaceutical care of patients with cancer through education, communication, research and innovation by an alliance of hospital, community and academic pharmacists, pharmacy technicians, those in the pharmaceutical industry and other healthcare professionals.

Public Benefit

These activities are undertaken to further the charitable purposes for the public benefit and the trustees believe that these activities satisfy the charity commissions general guidance on public benefit.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Achievements and performance

The role of BOPA in supporting and provided educational and training resources has increased and the scope and breadth of the projects and advocacy roles we have been involved with has widen. In light of this we have seen our BOPA membership increasing, for example in August 2025 we had 1093 paid members, 2501 free members and 30 corporate members. Additionally, since the launch of the website in 2019, BOPA has received over 3000 networking and clinical queries. Examples of BOPA's key achievements are described below.

Let's Communicate Cancer

After much work the LCC 3-year review was completed in February 2025. The process involved advertising and recruiting reviewers, preparation of an SOP, talking through the review points submitted to decide which required action, implementation of the actions, reinstallation of changed elements, checking media quality of materials was maintained.

LCC development documents are gradually being transferred from Jackie to the BOPA drive. Responsibility for LCC is being handed over to the Education and Training sub-committee. A new LCC Lead Jennifer Allen is in post and is handling enquiries and progressing LCC.

Work was carried out on LCC to make the new Play Your Part materials more visible in the modules rather than solely situated on the Cancer Hub. The red flag animation videos are now in Module 1 along with series 1 of the factsheets. Other series of factsheets are situated in Modules 2 and 3 as appropriate.

Material on the NHS E-learning for Health website is now out of date so negotiations between BOPA and the E-lfh teams are underway to inform users this is the case.

The LCC lead will preside over the current Royal Society Prevention for Health accreditation.

A grant has been received from Ipsen to examine the usefulness of LCC to other professions such as nursing and medicine. This work is being undertaken by the BOPA special interest group looking at community support of advanced cancer patients (CASPC).

Further work is required by all areas of BOPA to advertise and increase uptake of the valuable LCC resource.

The digital sub-has been very busy supporting and promoting various events with a variety of website uploads and communications from other sub-committees including:

- Research webinar sessions
- EDI webinar sessions
- Education & Training webinar sessions
- Let's Talk About SACT - a BOPA Podcast
- BMT education sessions
- Introduction to Cancer Course
- Updates to Let's Communicate Cancer
- Uploading new resources / policies
- E learning modules e.g. Myeloma, Managing Chemotherapy Nausea & Vomiting, Pancreatic Cancer
- Conference promotion
- Promoting research surveys
- Communication of all important updates in the cancer care community

- Joined a further social media platform – Bluesky <https://bsky.app/profile/bopa.org.uk>, please follow us!

The subcommittee also respond to and reply to membership and website enquiries.

Website updates:

- #BOPA2024 Conference videos uploaded on to website
- Updates to SACT verification hub page BOPA SACT Verification HUB - BOPA
- Updates to Let's Communicate Cancer (LCC) and LCC2: Play Your Part Series
- New discussion forum of New-to-Cancer members
- Updates to website exec and subcommittee pages
- Regular website maintenance

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Research Subcommittee

The aim of the BOPA Research Committee is to lead, develop and encourage high quality oncology/haematology pharmacy practice research and thereby increasing knowledge and promoting excellence in the care of cancer patients. Our main roles include

- Building a framework/infrastructure for collaborative working
- Leading the development of the research stream of the annual BOPA conference, including the submission and judging of abstracts

Promoting research, audits, service evaluation and innovation amongst the BOPA membership by signposting existing resources and developing materials accessible through the BOPA website

Key achievements in 2024-2025

	During the period of 24/25, we provided 3 webinars. • March 2025: Unseen and unheard: The medicine-related needs of older people with sensory impairment (OPwSI) • April 2025: New Models of Care • September 2025: Demystifying Systematic Reviews Future planned webinars include: • November 2025: Covidence 101 • December 2025: Data extraction overview • 2026: New models of care
PRUK/BOPA grant	The 2023 PRUK/BOPA grant was awarded to Lisa Macleod who will be completing a project titled: 'A Realist Evaluation of CloseHER2Home, a community pharmacy-led cancer treatment pathway'.
Collaborative Research	A dedicated workstream has recently restructured to enhance research collaboration across the BOPA community. This refreshed approach aims to foster inclusive engagement and create a dynamic platform for all members to contribute to research initiatives.

	Supporting members in initiating, developing, and disseminating research. Key objectives include: • Create a database/research directory where members can register projects and research interest • Promote collaborative working group at the BOPA symposium • Identify and overcome barriers for collaborative work e.g. dissemination of standard data sharing agreements and contracts • Set up a collaborative research project as a proof of concept. We have identified a project around 'equity of access to new treatments' Key outcomes: • Increased engagement with research • Increased no of multi-centre abstracts to be submitted to BOPA symposium • Increase average number of subjects per BOPA abstract submitted
Abstracts	We received 174 abstracts for the 2025 conference. Five have been selected for Oral presentation (Plenary), 5 for the highly commented poster presentations, 124 for posters and 40 were rejected. There were 2 abstracts received under the service improvement and New Models of Care category which have been invited to present as at future My Research Webinar. Last year's abstract booklet published in the Journal of Oncology Pharmacy Practice can be found here.
BOPA conference 	The research stream at the BOPA conferences remains strong with multiple sessions including presentations from Professor Christine Bond and Dr Ruth Miller. Our focus this year is developing our members to be better equipped to undertake research.
Advanced Pharmacy Study Day	We presented at the BOPA Advanced Pharmacy Study Day in Jun 25 titled <i>"Getting Started with Research: A Practical Guide to Begin and Thrive."</i> Now in its second year, this well-attended event aims to support senior pharmacists pursuing RPS Advanced Credentialing or Consultant Pharmacist Credentialing. The study day provides practical guidance to help attendees generate evidence for the research pillar, a key component of the credentialing process.
Mentoring	Since the creation of this expert mentorship list in Sept 2022, we now have 29 experienced pharmacists who have volunteered to support BOPA members to develop research projects, service evaluations/innovation projects or audits. Check out https://www.bopa.org.uk/research-support-list/.

Cancer pharmacy technicians	The research subcommittee and pharmacy technician subcommittee conducted a national survey on workforce distribution, training received and perceived gaps to provide insight into aligned post-registration training framework and strengthening education pathways and work plan standardisation. We will be presenting a poster at the BOPA conference 2025.
Future activity	We are exploring ways of using AI to support with the subcommittee activities.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

The education and training team continued to deliver high quality education and training resources, key worked centered on the areas below:

E-Learning	• Since the beginning of 2025 we have launched 2 more modules: • CINV • Multiple myeloma • Currently in progress CLL module due to launch in November 2025 • New agreement with GCA and funding secured for 3 more modules by the end of 2025: • Prostate • Gastric • Oesophageal • Recent funding for another module for the beginning of 2026 • SOP for SME recruitment process developed and approved • Talks with GCA with regards to developing accredited courses on leadership, research, development
BOPA Passport	• 2400 users as of Sept 2025 • Major update of all Passport content available from August 2025 • Working with RPS for long-term endorsement of the Passport • Working with EBMT colleagues to allow for European use • New UK Wide Training Pack to support Passport use – launching at BOPA 2025. 2025/26 workplan - Development of paediatric resources including POSCU module and paediatric transplant. - Focus on advanced therapies.
Introduction to Cancer	<u>Over 140 attendees to an ITC event in the last year!</u> • Two successful courses: • London Nov 2024 (80 delegates) • Leeds May 2025 (64 delegates) • NEW sessions introduced for 2025 Introduction to Haematology and Introduction to Paediatric Oncology - great feedback! • Planning underway for the next ITC event, likely early 2026 in Scotland • Working with ISOPP to develop an international “Foundations in Cancer Course”
Webinars	• Successful year so far webinars with very good attendance from BOPA members. • So far, we had 5 webinars, one of which was the International COSA, BOPA, CAPHO, ISSOP. • In conversation to have two more of the international webinars organised hopefully by the end of the year. • Two AI webinars took place in the last 2 months with 1 more to be organised in the near future. • New 3-part webinar series for systematic reviews to take place in November/December with open access to non-paying members.
Advanced Practice Study Day	• Launched in 2024, the BOPA Advanced Practice Study Day for pharmacists seeking to explore advanced roles and career development. • Over the past two years, we've welcomed more than 30 delegates • In 2025, we introduced a modest delegate fee, yet attendance increased compared to the inaugural. Feedback has been consistently positive, and we enhanced the programme in year two based on delegate • The study day offers pharmacists a unique opportunity to gain insight into advanced practice pathways, develop professionally, and connect with peers across the UK.

	Looking ahead, we plan to continue evolving the study day to meet the needs of our members.
Podcasts	9452 all-time downloads as of 26/8/25 42 episodes published - Reflected on feedback from last year- peer review of journals included - Continuing to publish one episode per month on average. - Feedback continues to be positive - In 2026 we would like to cover: dietetics, sexual health, menopause and much more
Lets Communicate Cancer	- Handover to new clinical lead in June 2025 - Migration from eLearning for Health to NHS Learning Hub started, due to complete Oct 2025. Note eLearning for Health content is out of date so a holding message will be placed on the content to direct users to the Cancer Hub on the BOPA website in the interim - Funding sources to update eLearning for Health/NHS Learning Hub to be explored - Content review planned for 2026
Consultant Pharmacist Credentialling Support	- BOPA poster accepted re last year's credentialing webinar series and questionnaire. - Proposal to set up a SIG for Cancer Credentialling Pharmacists - webinars will move to this group, as well as advanced practice framework, support for portfolio completion etc.
Universities Project	- Slides developed and waiting design, education and EDI review - Currently contains 5 recordings from pharmacists from backgrounds of chief pharmacist, charity lead, QA, private sector and ISOPP 2 pilot sites selected to trial presentation – one for pharmacists and another for pharmacy technicians - Plan for survey to be distributed to recruit BOPA members to speak at nearby Universities

The EDI sub-committee consists of 15 members and 3 recently recruited interns. In the past 12 months, it's been very active in delivering BOPA's commitment to building a diverse, equitable and inclusive community for all members, non-members and patients in cancer care.

Key Achievements for the past 12 months

Clinical considerations for the safe and inclusive prescribing for trans gender and non-binary patient	This work is in collaboration with OutPatients (a charity supporting and amplifying LGBTIQ+ voices in cancer care). The TRANScribing guideline is now available on BOPA and OUTpatients website and published in BPS official journal Collaborations with European Cancer Organisation for wider exposure in Europe.
Publication	TRANScribing: Clinical considerations for safe and inclusive prescribing for transgender and non-binary patients v2 John & Stewart have applied for a Gilead clinical fellowship to accelerate this work (decision expected October 2025). John will also present this at the Pharmacy Show and possibly at CPC North 2025 in Manchester.

Review of BOPA Educational Materials	We are developing a checklist of EDI considerations to guide the design of educational materials for BOPA. Once the checklist has been approved, we will begin reviewing the most frequently accessed documents as a priority and apply the checklist to promote inclusive language throughout BOPA's website. This work is being carried out in collaboration with the E&T Subcommittee.
Re-survey of membership reception of the EDI engagement	Equity, diversity, and inclusion in oncology pharmacy practice: Everyone's business. We have resurveyed BOPA members at 2024 conference with re-designed questions, taken into account feedback that we have received from the first survey. However, the response rate was very low (8 responses in total), and we are working towards improving engagement within our subcommittee.
Transatlantic collaborations: Canada	Jurga presented BOPA EDI survey results (2022), our current workstreams and her recently published scoping review results (Scoping review identifying interventions that have been tested to optimise the experience of people from ethnic minority groups receiving systemic anticancer therapy (SACT)) at ISOPP. This has generated interest to work collaboratively on several projects. Our survey is going to be adapted and used to gather views of cancer pharmacy workforce in Canada, this will generate additional publications with BOPA being acknowledged as a collaborator. Jurga has joined ISOPP EDI subcommittee in 2025.
Transatlantic collaborations: USA	We had Mo Adedipe presenting at one of our EDI meetings and we are building links to work together on future research projects to yield meaningful impact.
Transatlantic collaborations: Australia	Pascale presented Trans-cribing guidelines. Started collaboration with

	Stewart and CEO Prof Dorothy Keefe to introduce the guidelines in the 'optimal care pathway'. Interest from Gilead Australia on TRANscribing guideline
National and international Visibility	Nordic Social Pharmacy Conference – Shereen presented qualitative work on diverse patient experiences (June 2025, Glasgow)
Collaboration with Research Subcommittee	BOPA research committee is reviewing the process of supporting poster presenters at conferences to carry on with their research and start building collaborations between large and small Trusts where similar interests in research exists, thus enabling junior researchers to build their research portfolio and grow number of publications.
Key Performance Indicators (KPI) taskforce	Currently, BOPA does not have a set of Key Performance Indicators (KPIs) aligned with its strategic pillars or with standard EDI KPIs used across industry. As a result, many projects are progressing in directions shaped by personal interest rather than organisational priorities. For the next year ahead, we aim to establish clear KPI's, that will enable: • Differentiation between projects aligned with BOPA's strategic aims and those that are more individual/clinical in nature. • Internal and external benchmarking for performance review and reporting. • Greater organisational accountability with tangible outputs and outcomes (e.g., conference exposure, collaborations, publications). We have already created a dedicated taskforce to develop and oversee BOPA KPIs, ensuring focus on a small number of strong, long-term projects,

	complemented by achievable shorter-term initiatives. This will strengthen accountability, align activity with strategy, and support BOPA's growth as a professional organisation.
Kingston University MPharm student projects:	EDI related projects: 1. Inclusive patient care consultation framework for cancer patient's publications in progress (minority ethnic groups, elderly, physical disability and neurodiversity) (Samira and Wanauscha) 2. Inclusive patient care consultation framework piloting in practice at the RMH. (Karman and Iqra) 3. Intersectionality awareness in healthcare professionals 4. Inclusive consultations in learning disability 5. BOPA Subcommittee diversity audit 6. Virtual pharmacy clinic pilot for families of children with cancer (collaboration with Larsen's Pride and GOSH)
Conference updates	Three students have been accepted for Posters at BOPA 2025 conference presenting EDI research Samira, Wanauscha, and Soonia Jakiny This year we have asked all the presenters in the conference to include a slide or two of how their work is adapting the EDI framework. We have decided to bring in the EDI award for the next conference (2026) EDI stand rota to be staffed at BOPA 2025 conference
Policy & Advocacy	1. Subcommittee to sign joint letter to Secretary of State (re: 10-year cancer plan) 2. BOPA statement for the HRA inclusion and diversity Pilot guidance
Interns	We have recruited 3 interns to help with current EDI workstreams: Samuel, Keira and Aini.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

This was another productive year for the GAP members engaged in a variety of projects covering the full range of BOPA activities. To aid committee members support projects which impact on pharmacy staff working in cancer services, the committee has updated its terms of reference to better reflect the evolving role of pharmacy staff and their role in supporting patients with cancer. We will continue to provide governance oversight, both within BOPA ensuring clarity and accountability for the membership, and for BOPA's engagement with the outside organisations, ensuring that collaboration represent the best interests of BOPA, its membership and the wider oncology pharmacy profession. We continue to advocate for the role of pharmacy professionals within cancer services and promote continuing excellent work undertaken by BOPA and its members. We will also continue to publish position statements on behalf of the BOPA membership, ensuring that we speak as one body on areas of critical importance to oncology pharmacy, providing support and guidance as needed.

A summary of the activities of the committee are summarised below:

UK Pharmacy Research Advisory Board (UK PRAG)

In November GAP members contributed to the content of the UK PRAG groups pharmacy research strategy seeking to further embed the role of clinical-academia and research capacity within the workforce.

UKSB – IT policy

GAP members have played a key role in reviewing the latest update of the national UK SACT Board intrathecal policy. Members have helped to ensure that this policy is reflective of changes to provision of IT chemotherapy, challenging outdated practices and ensuring that patient safety is maintained through clear and evidence-based practice.

UKSB – hypersensitivity guidance

In May members have helped to review and contribute to the UK SACT board hypersensitivity to chemotherapy management guidance. This has helped to ensure that national guidelines reflected best practice principles.

Initial standards for pharmacy technician verification

In April GAP collaborated with the pharmacy technician committee to produce initial draft guidance regarding the potential role of pharmacy technicians in verification. This highlighted several areas of good practice which has been developed by early adopter sites for wider consideration.

UKSB Standardisation of SACT reviews

In June members helped to review the initial UK SACT board guidance regarding standardisation of SACT reviews by non-medical healthcare professionals. This ongoing work has involved extensive collaboration between GAP members, the BOPA exec, consultant pharmacist group and UK SACT board. Given the importance of this development to BOPA members working in advanced practice roles reviewing patients GAP have worked to ensure that this guidance supports the safe and effective practice of its members.

Develop guidance for BOPA endorsement of training programmes developed by external bodies

GAP have worked alongside the education and training committee to ensure a consistent approach to requests for endorsement of training programmes developed by external bodies. This guidance provides clarity for BOPA and its members as well as consistency for external bodies seeking to collaborate with BOPA.

Support and Collaborations

Supported the establishment of the new BOPA AI specialist interest group seeking to define the role of this emerging technology within oncology pharmacy practice.

Supported the NHS England Aseptics Infusion Board as part of workforce strategy developments to ensure rationale use of aseptic manufacturing capacity.

Conference Presentations

The GAP committee has worked to support BOPA members to present at a range of conferences within the past 12 months including, the pharmacy show, HSJ cancer forum, the RPS conference and CPC north.

Changes to GAP Co-chairs in 2025/2026

After supporting the work of the GAP committee as co-chair for 8 years Rhiannon is stepping down. The GAP members would like to thank her for her tireless work in driving forward changes to national policy that GAP members have contributed to. Rhiannon has helped to steer BOPA and the oncology pharmacy profession through a number of challenges during her tenure (Covid) and always acted with commendable attention to detail and good humour. Rhiannon will be replaced by David Mace who will assume a role as co-chair in November 2025. After six years of dedicated service as co-chair, Andy is stepping down to pursue an exciting new chapter—a PhD. Andy's leadership, insight, unwavering commitment and pragmatism have made a lasting impact, and GAP are very grateful for his contribution. Andy will be replaced by Jessica Pealing from January 2026.

Both Rhiannon and Andy will remain as members of the GAP committee and help to support the new chairs as they develop within the role. GAP are delighted to welcome David and Jess into their new roles

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

The conference sub-committee had another productive year and delivered another successful conference in Birmingham 2024, alongside the executive committee.

One significant difference to previous conferences, was the inclusion of an award ceremony at the Gala Dinner. Winners of the research awards, BOPA fellowship and the new Above and Beyond Award were recognised at this ceremony, whereas previously it has been on the Sunday morning. There was overwhelming positive feedback about this, and so the subcommittee have made the decision to repeat this at the Belfast Conference.

We have also responded to feedback ensuring we make the conference as welcoming as possible for 'first timers' and those coming on their own. We have several things planned to improve this in Belfast.

See the conference video and all information on the 2024 conference here: [27th Annual BOPA Conference – Birmingham 2024 - BOPA](#)

2024 Birmingham Stats:

- 428 HCPs in attendance (total attendees 758)
- 52 exhibitors
- 130 posters

Benefit to the public

As an organisation promoting excellence in the pharmaceutical care of patients with cancer, BOPA provides up-to-date resources for academic pharmacists, pharmacy technicians, those in the pharmaceutical industry and other healthcare professionals. Thereby promoting up-to-date safe and efficient practice through education, training and through participating in collaborative research both nationally and at a global level. In 2025 BOPA also created a Patient and Public Involvement Specialist Advisory Group (*Cancer Community Partners Group* - [Cancer Community Partners Advisory Group - BOPA](#))

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Activities undertaken to benefit the public

1. Let's Communicate Cancer project. The aim of the project is to educate and up-skill community pharmacists to engage with the public in the community setting with confidence and developing a knowledge base around cancer and its treatments.
2. The development of podcast to provide education and training using a new technology platform.
3. Annual BOPA symposium: Providing educational sessions to our members, on areas such as clinical management in cancer, good practice research methods (e.g., engaging with patients, public and carers) and scientific updates. This ensures our members have the knowledge, skills, and confidence to manage and work with cancer patients at their place of work.
4. The publication of the "Clinical considerations for the safe and inclusive prescribing for trans gender and non-binary patients". This work was completed in collaboration with OutPatients (a charity supporting and amplifying LGBTIQ+ voices in cancer care).
5. BOPA Submission for the National Cancer Plan for England 2025 – Call for Evidence - [BOPA Submission for the National Cancer Plan for England 2025 - Call for Evidence - BOPA](#) Patient and Public Involvement Specialist Advisory Group (*Cancer Community Partners Group* - [Cancer Community Partners Advisory Group - BOPA](#))

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Financial review

Trustees'/members' expenses for services

As a charitable organisation members and the three trustees are eligible for travel expenses, team building exercises and hotel accommodation. In this financial year the total cost is £1,999.

Reserve accounts

The Charity holds cash funds of £119,859, split between Nat West Bank accounts and a Scottish Widows account, of which £68,941 are restricted.

The reason for holding these reserves is:

1. In the event of a reduction in income the charity will be able to continue to provide its core functions and cover all existing fixed costs and commitments e.g., website maintenance.
2. The charity provides an annual educational event. In the normal course of events these meetings are at least "break even". However, there is the risk that the income for this meeting may be below the costs associated with running the meeting, and BOPA will be liable for this shortfall.

Summary of accounts

The total income received was £143,086 and the total payments made were £186,522.

This gave BOPA net expenditure of £43,436 for the year, and total assets/funds of £119,859, split between unrestricted funds of £50,918 and restricted funds of £68,941.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Plans for the future

1. To continue to collaborate with national and international (oncology) pharmacy groups to maintain and consolidate its professional and advocacy role.
2. During 2025-2026 BOPA will continue to develop and provide high quality education and training materials for all their members.
3. BOPA is also keen to develop and continue educational scholarships for its members and to fund research into Pharmacy Practice Research where there is a focus on cancer.
4. The BOPA 2025 symposium will be delivered as a face-to-face in London, England.
5. Continue collaboration with Specialist Pharmacy Groups and Professional Leadership Bodies to work together to have a unified Pharmacy voice within the UK.
6. Continue with strategy development within individual Subcommittees after vision publication - [About BOPA - BOPA](#)

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Declaration

Signed on behalf of the charity's trustees

Signature



Full Name

Mr Joseph Williams

Position

Chair

Date

19 January 2026

Signature



Full Name

Ms Shereen Nabhani-Gebara

Position

Vice -Chair

Date

19 January 2026

Signature



Full Name

Mr Rob Duncombe

Position

BOPA Trustee

Date

19 January 2026

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

BRITISH ONCOLOGY PHARMACY ASSOCIATION RECEIPTS AND PAYMENTS ACCOUNT YEAR ENDED 31 MARCH 2025

	Unrestricted funds	Restricted funds	Total	Total
	Year ended 31/03/2025	Year ended 31/03/2025	Year ended 31/03/2025	Year ended 31/03/2024
	£	£	£	£
Receipts:				
Members' subscriptions	91,528		91,528	87,543
Fees	0		0	55
Interest	1,435		1,435	1,329
Other	1,123	4,000	5,123	0
Grants:				
Pfizer - LCC		5,000	5,000	0
Ipsen open access paper		5,000	5,000	0
Greenlight		2,100	2,100	0
Bayer		15,000	15,000	0
Medac Pharma - BMT			0	1,500
Gilead - BMT			0	500
Ipsen - CASPCC			0	3,000
Takeda - BMT		2,000	2,000	1,500
Incyte - ISOPP			0	8,500
Roche - ISOPP			0	15,000
Astra Zeneca - education and training			0	20,000
Bristol Myers Squibb - education and training		2,800	2,800	7,000
IPSEN - Advanced Cancer Webinar			0	5,100
Gilead - BOPA Grant		4,800	4,800	5,200
Bristol Myers Squibb - Not normal for you			0	10,000
Sanofi		2,800	2,800	0
Eli Lilly		5,500	5,500	0
Greenlight		2,100	2,100	0
	94,086	49,000	143,086	166,227
Payments:				
Travel	1,999		1,999	3,866
Expenses			0	0
Digital	9,691		9,691	35,859
Symposium costs	21,724		21,724	24,298
Accountancy	5,400		5,400	2,268
Professional indemnity insurance			0	968

Insurance			0	247
Online banking			0	80
Secretariat	6,385		6,385	2,010
Audit research			0	0
Education - LCC			0	69,005
Educational	15,212	57,139	72,351	10,893
Education - intro to oncology	8,567	9,486	18,053	24,501
Education - podcast	2,200		2,200	3,605
Education - webinar			0	1,135
Life in a day/Day in the life			0	12,906
BOPA grants		654	654	12,760
Grants		4,866	4,866	0
Legal fees	2,579		2,579	3,120
Media	3,978		3,978	500
Abstract	10,214		10,214	2,675
SACT passport	25,875		25,875	44,455
Sundry	553		553	35
Prize money			0	2,000
	114,377	72,145	186,522	257,186
Net payments/receipts	-20,291	-23,145	-43,436	-90,959
Cash funds brought forward	71,209	92,086	163,295	254,254
Cash funds carried forward	50,918	68,941	119,859	163,295

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

BRITISH ONCOLOGY PHARMACY ASSOCIATION SUMMARY OF ASSETS YEAR ENDED 31 MARCH 2025

	31/03/2025	31/03/2024
	£	£
Nat West current account	26,089	60,960
Nat West reserve account	8,990	18,819
Scottish Widows account	84,780	83,516
Total	119,859	163,295


The Accounts were approved by the Committee on 19 January 2026




Joseph Williams - Chair



Shereen Nabhani-Gebara - Vice-Chair



Dharmisha Chauhan Co-Treasurer



Anish Tailor Co-Treasurer

Accounts

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION

REPORT AND ACCOUNTS

FOR THE YEAR ENDED

31ST MARCH 2024

REGISTERED CHARITY NO. 1065026

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

CONTENTS

	<u>Page</u>
Trust Information	2
Independent Examiner's Report	3
Trustees Annual Report	5
Receipts and Payments Account	12
Statement of Assets and Liabilities	14

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

TRUST INFORMATION

Registered Charity No. 1065026

Trustees Robert Duncombe
Emma Foreman
Joseph Williams

Treasurer Anish Tailor
Dharmisha Chauhan
Shumi Tattersfield

Independent Examiner Barry Fine

Address c/o GBH Law,
7/8 Innovation Place,
Douglas Drive
Godalming,
Surrey GU7 1JX

Bankers National Westminster Bank plc

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

I report on the Accounts of the Association for the year ended 31st March 2024 which are set out on pages 12 - 14.

Respective Responsibilities of the Trustees and Examiner

The charity's trustees are responsible for the preparation of the accounts.

The charity's trustees consider that an audit is not required for this year under section 144 of the Charities Act 2011 (the Charities Act) and that an independent examination is needed.

It is my responsibility to:

- examine the accounts under section 145 of the Charities Act,

- to follow the procedures laid down in the general directions given by the Charity Commission (under section 145(5)(b)) of the Charities Act, and

- to state whether particular matters have come to my attention.

Basis of Independent Examiner's Report

My examination was carried out in accordance with the General Directions given by the Charity Commissioners. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the Accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)**

Independent Examiner's Statement

In connection with my examination, no matter has come to my attention:

- 1) which gives me reasonable cause to believe that in any material respect the requirements
 - a. to keep accounting records in accordance with Section 130 of the Charities Act, and
 - b. to prepare Accounts which accord with the accounting records and comply with the accounting requirements of the Charities Act.have not been met; or
- 2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the Accounts to be reached.

Name. B. Fine FCA
Address Parkgates
Bury New Road
Prestwich
Greater Manchester
M25 0JW

Signed 
Dated... 8.11.2025

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

BOPA is an unincorporated organisation governed by its constitution.

Charity Number 1065026

Administrative Details

Principal address: 39 Oakley Road, Luton, Bedfordshire, LU4 9PT

Member	Role within BOPA	Date enacted
Joe Williams	Chair	
Shereen Nabhani-Gebara	Vice Chair / EDI Co-Chair	September 2023
Emma Foreman	Past Chair	
Jess Pealing	Secretary	
Clayton Wong	Co-Secretary Elect / Ind Sector Rep / Digital Co-Chair	September 2023
Michal Sladkowski	Co-Secretary Elect / E&T Co-Chair / Podcast	September 2023
Dharmisha Chauhan	Treasurer	
Anish Tailor	Treasurer	
Shumi Tattersfield	Co-Treasurer Elect	September 2023
Mollie Bishop	Technician Rep	
Colm Doody	Industry Rep	
Rhiannon Walters-Davies	GAP Co-Chair	
Nisha Shaunak	EDI	
Alice Tew	Symposium / IO Co-Chair	

Structure

Members of the committee are elected for a three year term of office by the voting members through an electronic ballot. Each candidate provides a written statement in support of their application. These statements are electronically submitted to the members. The results of the election are announced at the Annual Symposium. Members can serve a maximum of two consecutive terms of office on the committee.

This committee then votes for the officers of Chair and Treasurer between themselves.

The association does not require any fundraising or grant-making activities. It is self-funding by members subscriptions, with additional sponsorship from the pharmaceutical industry for key projects such as e-Learning.

Decisions are made at the monthly committee meetings on behalf of the membership. The committee have several sub committees which feed back to the committee their decisions and ideas on behalf of the membership.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Sub committees:

1. Annual Symposium
2. Education and Training
3. Research
4. Community and Primary Care Pharmacy
5. Digital
6. Guidelines, Advocacy and Publications
7. Pharmacy Technician
8. Workforce and Capacity
9. Equity, Diversity, and Inclusion

Governance

Due to the nature of this charity no policies are in place to recruit and train trustees. Generally, those people elected by the members of the association are then responsible for the maintenance and safe handling of the Charity on behalf of the members.

Any decisions that require the membership to be involved in, such as national consultation documents, the document is placed on the BOPA website and emailed throughout the membership for comments to be received by the reference sub-committee who will then collate the response and return it.

The association works closely with the NHS England Cancer Area Team Pharmacists, and other relevant (oncology) pharmacy groups.

Objectives

The stated aim of BOPA is to promote excellence in the pharmaceutical care of patients with cancer through education, communication, research and innovation by an alliance of hospital, community and academic pharmacists, pharmacy technicians, those in the pharmaceutical industry and other healthcare professionals.

Public Benefit

These activities are undertaken to further the charitable purposes for the public benefit and the trustees believe that these activities satisfy the charity commissions general guidance on public benefit.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Achievements and performance

The role of BOPA in supporting and provided educational and training resources has increased and the scope and breadth of the projects and advocacy roles we have been involved with has widen. In light of this we have seen our BOPA membership increasing, for example in September 2024 we had 925 paid members, 1928 free members and 31 corporate members. Additionally, since the launch of the website in 2019, BOPA has received over 2000 networking and clinical queries. Examples of BOPA's key achievements are described below.

October 2023 saw the launch of Let's Communicate Cancer 2, Play Your Part and the new BOPA and NPA Cancer Hubs. The underlying aim of the sub-committee this year was to allow space to refocus following such major project work. This year has seen the transfer of the Let's Communicate Cancer maintenance role be overseen by the BOPA Education and training sub-committee. A full review of content was due at the 3 year post launch point. A special interest group called CASPC – Community Approach to Advanced Cancer Support has been formed. This group is currently seeking funding to carry out areas of work linking primary and secondary care in the care of cancer patients.

The digital sub-has been very busy supporting and promoting various events with a variety of website uploads and communications from other sub-committees including:

- Research webinar sessions
- EDI webinar sessions
- Education & Training webinar sessions
- Let's Talk About SACT - a BOPA Podcast
- Introduction to Oncology Course
- Updates to Let's Communicate Cancer
- Uploading new resources / policies
- E learning modules e.g. UTIC, Introduction to Immuno-oncology, Level 1 training
- Conference promotion
- Promoting research surveys
- Communication of all important updates in the cancer care community

Website updates:

- #BOPA2023 Conference videos uploaded on to website
- Launch of new SACT verification hub page BOPA SACT Verification HUB - BOPA
- Development of Memberships FAQ section BOPA membership FAQs - BOPA
- Member search updated
- Member profiles now include Orchid ID/google scholar
- Agreement for code of conduct for BOPA now a requirement within the membership
- Member group pages updated to include 'circles' – improving aesthetics
- Pop up added to website for free associate members to illustrate the benefits of full membership
- Regular website maintenance
- Trello board subscription to help organise the workload of each of the subcommittees

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

The research sub-committee continues to host research webinars to ensure more pharmacy professionals engage and feel confident to conduct their own research projects and the research mentor support programme which started last year continues. To support pharmacy professionals in research, the subcommittee hosted 5 webinars. During the period of 23/24, we hosted seven webinars. Our hour long webinars, take place every 6-8 weeks at different times and on different days of the week to ensure accessibility. We invited BOPA members and external speakers to present at the 2023/2024 webinars:

1. Shared experience from SLOG pharmacy interest group
2. BOPA symposium 2023 poster discussion
3. UK Early Career Researchers Cancer Group
4. A DPharm journey
5. Real world experience of bispecific antibody Teclistamab in relapsed refractory multiple myeloma
6. A survey on understanding the gaps in SACT education to minority group cancer patients
7. Understanding global participation in gynae-oncology RCTs: a systematic review approach
8. Vulnerable groups as caregivers (women, LGBTQ, Indigenous populations)

In addition to the webinar the research committee we received 155 abstracts for the 2024 conference. Five were selected for oral presentation (Plenary) on 12th Oct 2024, five for the highly commended poster presentations on 12th Oct 2024, 121 abstracts accepted for poster presentation and 24 were rejected. We have added a new category 'Service improvement and new Models of Care' for the 2024 conference. All oral presenters have been invited to present at our My Research Webinar in 2025.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

The education and training team continued to deliver high quality education and training resources, key worked centered on the areas below:

E-Learning	- Breast cancer, lower GI, melanoma, and lung cancer modules have now been released with positive feedback. - Myeloma and CINV have been commissioned. With the aim of completion before the end of 2024. - Immunotherapy eLearning has also been published.
BOPA Passport	- Created wider sub-committee to manage ongoing passport developments. - Representation from England, Scotland and Wales. - Pharmacists and technicians involved in update. - New materials for core module; UTIC, IO eLearning. - Successful uptake across the 4 nations. - Positive feedback for the Core Module. - Interest spanning beyond the UK. - Preparing for BOPA symposium. - Ready to ask the membership to contribute new content - Work plan for the next year based on needs is underway. - New Scientist Publication here: tinyurl.com/mrykyvkz
Introduction to Oncology	- Two successful events in the last year: □ London Nov 2023 (80 delegates) □ Leeds March 2024 (60 delegates) - Demand continues to be high - fully booked for London Nov 2024 (80 delegates) - NEW session for 2024 on Genomics - great feedback! - Partnership agreed with Media1 for 2025 to support event management - New agenda (based on delegate feedback) to be launched for events in 2025
Webinars	Organised, hosted and co-ordinated 15 webinars • Over 350 registrants and 400 playbacks • Collaborations with national and international organisations and cancer charities including: APOPA CAPhO COSA ECO HOPAK ISOPP NCODA OUTPATIENTs SIOG SOBRAFO UK ECRC

	•Topic Highlights: Celebrate Pride Month Highlight from international conferences ISOPP Global Drug Shortages Webinar •2025: You Ask, We Listen!
--	---

The equity, diversity and inclusion subcommittee has been very active in the past 12 months in delivering BOPA's commitment to building a diverse, equitable and inclusive community for all members, non-members and patients in cancer care.

Key Achievements for the past 12 months

Clinical considerations for the safe and inclusive prescribing for trans gender and non-binary patients

This work is in collaboration with OutPatients (a charity supporting and amplifying LGBTIQ+ voices in cancer care)

The TRANScRIBing guideline is now available on BOPA website and -00UTpatients website
Safe and supportive prescribing in transgender and non-binary patients with cancer is **PUBLISHED** on the British Pharmacological Society Journal

Collaborations with NHSE to develop factsheets on care for transgender and non-binary patients. First Transgender Factsheet **PUBLISHED**, more factsheets to come
Best practice principles for inclusive care of transgender and non-binary patients is now available on the Pharmaceutical Journal
PJ article

Publication

Collaborations with European Cancer Organization for wider exposure in Europe
Equity, diversity, and inclusion in oncology pharmacy practice: Everyone's business. **PUBLISHED** in the Journal of Oncology Pharmacy Practice

Dissemination

Championing equity, diversity and inclusion (EDI) to support the pharmacy workforce and provide inclusive care

BOPA advocacy & visibility

Oncology Professional Care – May 2024
UK Oncology Forum – June 2024

Presentation on TRANScRIBing guideline has been arranged with Gilead Australia in October 2024

The American Society of Consultant Pharmacists September issue citing the TRANScRIBing guideline

Inclusive patient Care	EDI projects completed in 2024. LD & cancer part 1 completed – accepted for BOPA Conference 2024 Inclusive counselling for ethnic minority groups – manual script in preparation Advocacy & empowerment – accepted for BOPA Conference 2024 Role of pharmacy in the care of older patients – accepted for BOPA Conference 2024 and International Society of Geriatric Oncology (SIOG) presentation 2024 Role of pharmacy in supporting families of children with cancer – accepted for BOPA Conference 2024 Interventions to optimise care for people from minority and ethnic groups – manual script in preparation
Educational Webinar	To mark Pride Month, we collaborated with the E&T committee to organise a session on providing LGBTIQ+ Inclusive Care
Code of Conduct, EDI Complaint policy & Complaint form	Code of conduct policy has been implemented before membership application and renewal Complaint procedure is put in place to enable EDI related concerns to be raised and managed accordingly. Lessons learnt can be implemented to ensure BOPA and its members embrace EDI principle and culture
Conference	This year, there are 4 topic streams within the conference programme to address equity, diversity and inclusion in oncology practice
Further projects underway	EDI checklist for inclusive counselling: • Physical disability • Ethnicity & Age • Learning disability • Neurodiversity Members follow-up survey to evaluate engagement interests Cultural calendar – strategy to highlight themes EDI podcasts in 2025

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

This year has been highly productive for GAP members, who have engaged in a variety of projects spanning the full range of BOPA activities. We will continue to provide governance oversight within BOPA, ensuring clarity and accountability for the membership, and for BOPA's engagement with external organisations, ensuring that collaborations represent the best interests of BOPA, its members, and the wider oncology pharmacy profession. We remain committed to advocating for the role of pharmacy professionals within cancer services and promoting the excellent work undertaken by BOPA and its members. Additionally, we will continue to publish position statements on behalf of the BOPA membership, ensuring that we speak as one body on critical issues in oncology pharmacy, providing support and guidance as needed.

A summary of the activities of the committee are summarised below:

Declarations of Interests

The GAP committee continue to ensure appropriate governance of the BOPA Executive and Sub Committees by undertaking annual reviews of the declarations of interests from those required as per policy.

Fellowship Scheme

The GAP committee continue to have oversight of the Fellowship Scheme within BOPA.

SACT Consent

The GAP committee has contributed to this multi-agency report to help provide guidance and support to provider organisations in the context of SACT consent.

UK SACT Board- Intrathecal Policy Update

The GAP committee has contributed to the ongoing UK SACT Board update of this guidance to ensure that professional guidance remains relevant for in this critical area.

BOPA Vision and Strategy

The GAP committee members have worked closely with the members of the pillars of the BOPA Vision and Strategy to ensure that appropriate governance frameworks are adhered to.

UK SACT Board - Guidance on the management of anaphylaxis and hypersensitivity reactions in patients receiving intravenous systemic anti-cancer therapy

The GAP committee has contributed to the ongoing UK SACT Board update of this guidance to ensure that professional guidance remains relevant for in this critical area of oncology therapy.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

The symposium sub-committee had another productive year and delivered another successful conference in Wales in 2023 alongside the executive committee and our sponsors. Thank you to all involved.

2023 Statistics:

- 6th to the 8th October 2023, ICC Wales
- Attendance - 581 including exhibitors and 371 no exhibitors
- 45 exhibitors
- We received 113 abstracts for the 2023 Symposium. 5 were selected for Oral presentation (Plenary), 5 for the highly commented poster presentations, 86 for posters and 17 were rejected. There was 1 abstract received under the service improvement and New Models of Care category which was selected for oral and poster presentation.

Research Publication is now available in JOPP - Journal of Oncology Pharmacy Practice - Volume 30, Number 1_suppl, Feb 01, 2024 (sagepub.com)

Our annual symposium continues to be our biggest educational and networking event of the year.

Benefit to the public

As an organisation promoting excellence in the pharmaceutical care of patients with cancer, BOPA provides up-to-date resources for academic pharmacists, pharmacy technicians, those in the pharmaceutical industry and other healthcare professionals. Thereby promoting up-to-date safe and efficient practice through education, training and through participating in collaborative research both nationally and at a global level.

Activities undertaken to benefit the public

1. Let's Communicate Cancer project. The aim of the project is to educate and up-skill community pharmacists to engage with the public in the community setting with confidence and developing a knowledge base around cancer and its treatments.
2. The development of podcast to provide education and training using a new technology platform.
3. Annual BOPA symposium: Providing educational sessions to our members, on areas such as clinical management in cancer, good practice research methods (e.g., engaging with patients, public and carers) and scientific updates. This ensures our members have the knowledge, skills, and confidence to manage and work with cancer patients at their place of work.
4. The publication of the "Clinical considerations for the safe and inclusive prescribing for trans gender and non-binary patients". This work was completed in collaboration with OutPatients (a charity supporting and amplifying LGBTIQ+ voices in cancer care).

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Financial review

Trustees/members expenses for services

As a charitable organisation members and trustees are eligible for travel expenses, team building exercises and hotel accommodation. In this financial year the total cost is £3,866.

In this financial year meetings have continued to move back to face to face meetings post-COVID-19

Reserve accounts

The Charity holds cash funds of £163,295 split between a Nat West Bank account and a Scottish Widows account of which £92,086 are restricted.

The reason for holding these reserves is:

1. In the event of a reduction in income the charity will be able to continue to provide its core functions and cover all existing fixed costs and commitments e.g., website maintenance.
2. The charity provides an annual educational event. In the normal course of events these meetings are at least "break even". However, there is the risk that the income for this meeting may be below the costs associated with running the meeting, and BOPA will be liable for this shortfall.

Summary of accounts

The total income received was £166,227 and the total payments made were £257,186.

This giving BOPA a negative areas for the year of £90,959 and total assets/funds of £163,295 split between unrestricted of £71,209 and restricted funds of £92,086.

Plans for the future

1. To continue to collaborate with national and international (oncology) pharmacy groups to maintain and consolidate its professional and advocacy role.
2. During 2024-2025 BOPA will continue to develop and provide high quality education and training materials for all their members.
3. BOPA is also keen to develop educational scholarships for its members and to fund research into Pharmacy Practice Research where there is a focus on cancer.
4. The BOPA 2024 symposium will be delivered as a face-to-face in Birmingham, England.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Declaration

Signed on behalf of the charity's trustees

Signature



Full Name Mr Joseph Williams

Position Chair

Date 08/01/2025

Signature



Full Name Ms Shereen Nabhani-Gebara

Position Vice -Chair

Date 08/01/2025

Signature



Full Name Mr Rob Duncombe

Position BOPA Trustee

Date 08/01/2025

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

BOPA y/e 31/03/24

Receipts and payments account

	Unrestricted funds 23/24 £	Restricted funds 23/24 £	Total 23/24 £	Total 22/23 £
Receipts:				
Members' subscriptions	87,543		87,543	54,734
Fees	55		55	8,059
Interest	1,329		1,329	274
Grants:				
Pfizer - LCC				75,000
Ipsen open access paper				2,388
Amgen - training support				20,000
Pharmacy research				1,078
Medac Pharma - BMT		1,500	1,500	
Gilead - BMT		500	500	
Ipsen - CASPCC		3,000	3,000	
Takeda - BMT		1,500	1,500	
Incyte - ISOPP		8,500	8,500	
Roche - ISOPP		15,000	15,000	
Astra Zeneca - education and training		20,000	20,000	
Bristol Myers Squibb - education and training		7,000	7,000	
IPSEN - Advanced Cancer Webinar		5,100	5,100	
Gilead - BOPA Grant		5,200	5,200	
Bristol Myers Squibb - Not normal for you		10,000	10,000	
	88,927	77,300	166,227	161,533
Payments:				
Executive travel	3,856		3,856	2,601
Expenses			0	1,426
Digital	35,859		35,859	24,728
Symposium costs	19,098	5,200	24,298	14,778
Accountancy	2,268		2,268	2,160
Professional indemnity insurance	968		968	817
Insurance	247		247	272
Online banking	80		80	40
Secretariat	2,010		2,010	3,601
Audit research			0	15,958
Education - LCC	1,255	67,750	69,005	23,753
Educational	4,893	6,000	10,893	1,140
Education - intro to oncology	24,501	8,150	24,501	9,990
Education - podcast	3,605		3,605	
Education - webinar	435	700	1,135	
Life in a day/Day in the life	12,906		12,906	9,628
BOPA grants	12,760		12,760	13,156
Legal fees	3,120		3,120	
Media	500		500	
Abstract	2,675		2,675	
SACT passport	44,455		44,455	
Sundry	35		35	
Prize money	2,000		2,000	
	177,536	87,800	257,186	124,048
Net payments/receipts	-89,309	-1,650	-90,969	37,485
Cash funds brought forward	160,518	93,736	254,254	216,769
Cash funds carried forward	71,209	92,086	163,295	254,254

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

BOPA summary - y/e 31/03/24

Statement of assets and liabilities

	2023/24	2022/23
Nat West current	60960	153064
Nat West reserve	18819	18569
Scottish Widows	83516	82621
	254254	163295


The Accounts were approved by the Committee on 22 January 2025




Joseph Williams - Chair



Shereen Nabhani-Gebara - Vice-Chair



Dharmisha Chauhan Co-Treasurer



Anish Tailor Co-Treasurer

Accounts

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION

REPORT AND ACCOUNTS

FOR THE YEAR ENDED

31ST MARCH 2023

REGISTERED CHARITY NO. 1065026

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

CONTENTS

	<u>Page</u>
Trust Information	2
Independent Examiner's Report	3
Trustees Annual Report	5
Receipts and Payments Account	12
Statement of Assets and Liabilities	14

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

TRUST INFORMATION

Registered Charity No.	1065026
Trustees	Robert Duncombe Emma Foreman Seonaid McLachlan
Treasurer	Dharmisha Chauhan
Independent Examiner	Barry Fine
Address	c/o Dharmisha Chauhan, 39 Oakley Road, Luton, LU4 9PT
Bankers	National Westminster Bank plc

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)**

I report on the Accounts of the Association for the year ended 31st March 2023 which are set out on pages 12 - 14.

Respective Responsibilities of the Trustees and Examiner

The charity's trustees are responsible for the preparation of the accounts.

The charity's trustees consider that an audit is not required for this year under section 144 of the Charities Act 2011 (the Charities Act) and that an independent examination is needed.

It is my responsibility to:

examine the accounts under section 145 of the Charities Act,

to follow the procedures laid down in the general directions given by the Charity Commission (under section 145(5)(b)) of the Charities Act, and

to state whether particular matters have come to my attention.

Basis of Independent Examiner's Report

My examination was carried out in accordance with the General Directions given by the Charity Commissioners. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the Accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)**

Independent Examiner's Statement

In connection with my examination, no matter has come to my attention:

- 1) which gives me reasonable cause to believe that in any material respect the requirements
 - a. to keep accounting records in accordance with Section 130 of the Charities Act, and
 - b. to prepare Accounts which accord with the accounting records and comply with the accounting requirements of the Charities Act.have not been met; or
- 2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the Accounts to be reached.

Name. B. Fine FCA
Address Parkgates
Bury New Road
Prestwich
Greater Manchester
M25 0JW

Signed.....
Dated... 22 January 2024

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

BOPA is an unincorporated organisation governed by its constitution.

Charity Number 1065026

Administrative Details

Principal address: 39 Oakley Road, Luton, Bedfordshire, LU4 9PT

<u>Committee Members</u>	<u>Office</u>	<u>Dates acted if not whole year</u>
Emma Foreman	Co-Chair	
Joseph Williams	Co-Chair	
Jessica Pealing	Secretary	
Dharmisha Chauhan	Co-Treasurer	Started October 2022
Anish Tailor	Co-Treasurer	
Colm Doody		
Nisha Shaunak		
Molly Bishop		Started October 2022
Clare Geoghegan		
Lynn Ansell		
Bastiaan Buijtenhuijs		
Shereen Nabhani-Gebara		Started October 2021
Rebecca Devine		
James Clark		

Structure

Members of the committee are elected for a three year term of office by the voting members through an electronic ballot. Each candidate provides a written statement in support of their application. These statements are electronically submitted to the members. The results of the election are announced at the Annual Symposium. Members can serve a maximum of two consecutive terms of office on the committee.

This committee then votes for the officers of Chair and Treasurer between themselves.

The association does not require any fundraising or grant-making activities. It is self-funding by members subscriptions, with additional sponsorship from the pharmaceutical industry for key projects such as e-Learning.

Decisions are made at the monthly committee meetings on behalf of the membership. The committee have several sub committees which feed back to the committee their decisions and ideas on behalf of the membership.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Sub committees:

1. Annual Symposium
2. Education and Training
3. Research
4. Community and Primary Care Pharmacy
5. Digital
6. Guidelines, Advocacy and Publications
7. Pharmacy Technician
8. Workforce and Capacity
9. Equity, Diversity, and Inclusion

Governance

Due to the nature of this charity no policies are in place to recruit and train trustees. Generally, those people elected by the members of the association are then responsible for the maintenance and safe handling of the Charity on behalf of the members.

Any decisions that require the membership to be involved in, such as national consultation documents, the document is placed on the BOPA website and emailed throughout the membership for comments to be received by the reference sub-committee who will then collate the response and return it.

The association works closely with the NHS England Cancer Area Team Pharmacists, and other relevant (oncology) pharmacy groups.

Objectives

The stated aim of BOPA is to promote excellence in the pharmaceutical care of patients with cancer through education, communication, research and innovation by an alliance of hospital, community and academic pharmacists, pharmacy technicians, those in the pharmaceutical industry and other healthcare professionals.

Public Benefit

These activities are undertaken to further the charitable purposes for the public benefit and the trustees believe that these activities satisfy the charity commissions general guidance on public benefit.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Achievements and performance

The role of BOPA in supporting and provided educational and training resources has increased and the scope and breadth of the projects and advocacy roles we have been involved with has widen. In light of this we have seen our BOPA membership increasing, for example in August 2023 we had 865 paid members, 3421 free members and 25 corporate members. Additionally, since the launch of the website in 2019, BOPA has received over 2000 networking and clinical queries. Examples of BOPA's key achievements are described below.

Building on the success of the launch of Let's Communicate Cancer, the Community and Primary Care Pharmacy subcommittee have continued to grow the educational and training resources to improve cancer knowledge within this sector. Two new projects started this year, one called Not Normal For You? This project will be developing training resources to help community and primary care healthcare professionals to identify red flag cancer symptoms. The second project called Play Your Part which aims to develop materials too in the form of short red flag animations on breast, lung, genitourinary and blood cancers, including three series of factsheets. This project will support cancer prevention and early cancer diagnosis whilst providing education on key cancer treatments.

The digital sub-committee continued to team work incredibly hard to engage with our BOPA members with hybrid education and training events. The BOPA website continues to be updated to improve usability and functionality, as an example the search functionality on the website has been improved. New webpages have also been developed, e.g., development of a new research page in conjunction with the research subcommittee. The team increased social and media posts throughout the year, sharing educational resources and information, which in turn benefits the number of new pharmacy professionals joining BOPA. This year has also seen the launch of BOPA Podcast – [Let's Talk About SACT - a BOPA Podcast](#). The digital subcommittee in conjunction with the education and training subcommittee have developed 14 episodes which are currently available and more than 1660 downloads to date.

The research sub-committee continue to host research webinars to ensure more pharmacy professionals engage and feel confident to conduct their own research projects and the research mentor support programme which started last year continues. To support pharmacy professionals in research, the subcommittee hosted 5 webinars. During the period of 22/23, we published five webinars:

1. Role of the Pharmacist in Geriatric Oncology.
2. Tips for a successful submission for BOPA-PRUK grant opportunity.
3. Innovation & Efficiency in Administering Immunotherapy.
4. NIHR fellowship and internship respectively.
5. Update from ESMO breast Future collaborations with the E&T subcommittee.

In addition to the webinar the research committee received 113 abstracts for the 2023 Symposium. Of these, five were selected for oral presentation (Plenary), 5 for the highly commented poster presentations, 86 for posters and 17 were rejected and one abstract received a commendation under the service improvement and New Models of Care category which was selected for oral and poster presentation.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

The education and training team continued to deliver high quality education and training resources, key worked centered on the areas below:

E-Learning	• E&T Strategy for eLearning is now active with multiple pharma partners supporting the strategy. • Breast cancer and Lung cancer modules to be released ahead of BOPA Symposium. • The aim for 10 modules is in reach as these are nearly fully funded. • Bone Marrow Transplant modules released: Introduction to infection, Acute Graft Versus Host Disease and Fungal Disease.
Introduction to Oncology	• High demand. Long waiting lists and the event has “sold out” each time registration has opened. • Leeds March 2023 (50 delegates/day) • London June 2023 (55 delegates/day) • London Nov 2023 (80 delegates/day) • New 2-day format • More inclusive for technicians
Webinars	• Hosted 8 E&T webinars • Over 300 live participants and over 700 playbacks • Viewership from 25 countries (6 continents), including UK, Australia, Canada, US, UAE, Hong Kong, Ireland, Japan • International collaborations • Webinar topic Highlights: ○ LGBTIQ+ inclusive care ○ Genomics Series ○ Pharmacy Technician Roles in Oncology ○ Dual Perspective - Cancer Pharmacist & Patient

The equity, diversity and inclusion subcommittee started in January 2022 and in 2022/23 a key project outcome included a task and finish group to develop a guideline for the clinical consideration for the safe and inclusive prescribing for trans gender and non-binary patients. This work is in collaboration with OutPatients, a charity supporting and amplifying LGBTIQ+ voices in cancer care. This work was published in October 2023 to support clinicians within clinical settings.

This was another productive year for the Guidelines, Advocacy and Publications (GAP) sub-committee. The GAP members engaged in a variety of projects covering the full range of BOPA activities. To aide committee members support projects which impact on pharmacy staff working in cancer services, the committee has updated its terms of reference to better reflect the evolving role of pharmacy staff and their role in supporting patients with cancer. A summary of key activities of the committee below:

- **UK Commission on Professional Leadership within the Pharmacy Profession** - In February 2023 the UK commission on pharmacy professional leadership published its [report](#). BOPA was identified as a stakeholder organisation and has been invited to participate as a member of the new leadership forum.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

- **UK SACT Board - SACT Aseptic Capacity Pressures Report** -The GAP committee has contributed to this multi-agency report to help provide guidance and support to provider organisations in the context of ongoing challenges to provision of SACT services.
- **UKONS Acute Oncology - Acute Oncology Initial Management Guidelines** - GAP committee members contributed to reviewing and updating the content of this valuable [resource](#) in collaboration with UKONS.
- **RPS Professional Standards for Hospital Pharmacy Services** - The GAP committee has contributed to the ongoing RPS update of this guidance to ensure that professional guidance remains relevant and reflects the evolving role of pharmacy professionals working in cancer services.
- **Department of Health and Social Care Consultation - Pharmacy technicians and Patient Group Directives** - The GAP committee is working closely with the pharmacy technician committee to review this recent consultation and support pharmacy technicians working in cancer services.

The annual BOPA symposium is our biggest face-to-face educational event of the year was held in Liverpool, in which 341 healthcare professionals attended, including 44 exhibitors and 79 posters were presented. The event was well attended, and we continued to attract international participation. Overall, we were able to provide a high quality and educational conference, with the event being rated very positively by our members. Plans are now underway to host the next symposium as a face-to face event in Newport, Wales.

Our annual symposium continues to be our biggest educational and networking event of the year.

Benefit to the public

As an organisation promoting excellence in the pharmaceutical care of patients with cancer, BOPA provides up-to-date resources for academic pharmacists, pharmacy technicians, those in the pharmaceutical industry and other healthcare professionals. Thereby promoting up-to-date safe and efficient practice through education, training and through participating in collaborative research both nationally and at a global level.

Activities undertaken to benefit the public

1. Let's Communicate Cancer project. The aim of the project is to educate and up-skill community pharmacists to engage with the public in the community setting with confidence and developing a knowledge base around cancer and its treatments.
2. The development of podcast to provide education and training using a new technology platform.
3. Annual BOPA symposium: Providing educational sessions to our members, on areas such as clinical management in cancer, good practice research methods (e.g., engaging with patients, public and carers) and scientific updates. This ensures our members have the knowledge, skills, and confidence to manage and work with cancer patients at their place of work.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Financial review

Trustees/members expenses for services

As a charitable organisation members and trustees are eligible for travel expenses, team building exercises and hotel accommodation. In this financial year the total cost is £4,027.

In this financial year meetings were held both virtually and with one face-to-face event in December.

Reserve accounts

The Charity holds cash funds of £254,254 split between a Nat West Bank account and a Scottish Widows account of which £93,736 are restricted.

The reason for holding these reserves is:

1. In the event of a reduction in income the charity will be able to continue to provide its core functions and cover all existing fixed costs and commitments e.g., website maintenance.
2. The charity provides an annual educational event. In the normal course of events these meetings are at least “break even”. However, there is the risk that the income for this meeting may be below the costs associated with running the meeting, and BOPA will be liable for this shortfall.

Summary of accounts

The total income received was £161,533 and the total payments made were £124,048.

This giving BOPA a surplus for the year of £37,485 and total assets/funds of £254,254 split between unrestricted of £160,518 and restricted funds of £93,736.

Plans for the future

1. To continue to collaborate with national and international (oncology) pharmacy groups to maintain and consolidate its professional and advocacy role.
2. During 2023-2024 BOPA will continue to develop and provide high quality education and training materials for all their members.
3. BOPA is also keen to develop educational scholarships for its members and to fund research into Pharmacy Practice Research where there is a focus on cancer.
4. The BOPA 2023 symposium will be delivered as a face-to-face in Newport, Wales.

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Declaration

Signed on behalf of the charity’s trustees

Signature

Full Name Ms Emma Foreman

Position Chair

Date 22 January 2024

Signature

Full Name Ms Joseph Williams

Position Chair

Date 22 January 2024

Signature

Full Name Mr Rob Duncombe

Position BOPA Trustee

Date 22 January 2024

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

<u>Receipts and Payments Account 2022-2023</u>				
	Unrestricted Funds	Restricted Funds	Total	Total
	2023	2023	2023	2022
	£	£	£	£
<u>Receipts</u>				
Members Subscriptions	54,734		54,734	55,405
Fees	8,059		8,059	
Interest Receivable	274		274	86
<u>Grants</u>				
Ipsen - Day in the life				7,500
Oxford University -training				2,500
Pfizer - Watson research				6,500
Pfizer - Lets communicate cancer		75,000	75,000	
Ipsen open access paper		2,388	2,388	
Amgen - training support		20,000	20,000	
Pharmacy research		1,078	1,078	
GROSS INCOME	63,067	98,466	161,533	71,991

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

Receipts and Payments Account 2022-2023				
	Unrestricted Funds	Restricted Funds	Total	Total
	2023	2023	2023	2022
	£	£	£	£
<u>Payments</u>				
Executive Travel	2,601		2,601	759
Expenses	1,426		1,426	3,377
Digital	24,728		24,728	16,370
Symposium Costs	14,778		14,778	18,484
Audit / Accountancy	2,160		2,160	
Professional Indemnity Insurance	817		817	817
Insurance	272		272	
On-line banking	40		40	110
Secretariat	3,601		3,601	
Research - Sage Publication				4,320
Community Pharmacy project				5,104
Audit research	15,958		15,958	
Education - Lets communicate cancer	16,503	7,250	23,753	
Educational	1,140		1,140	5,481
Education - Intro to oncology	9,990		9,990	
Day in the life	9,628		9,628	9,044
Pfizer Watson research				6,500
Administration costs				1,230
BOPA grants	13,156		13,156	
TOTAL EXPENDITURE	116,798	7,250	124,048	71,596

Net Surplus (Payments) - Receipts	(53,731)	91,216	37,485	395
Cash funds last year end	214,249	2,520	216,769	216,374
Cash funds this year end	160,518	93,736	254,254	216,769

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

STATEMENT OF ASSETS & LIABILITIES		
Current Assets	2022/23	2021/22
	£	£
Current Account	153,064	115,852
Business Reserve Account	18,569	18,489
Scottish Widows Deposit Account	82,621	82,428
	254,254	216,769
Net Current Assets	254,254	216,769

The Accounts were approved by the Committee on 22 January 2024

..... Chair

..... Chair

..... Co-Treasurer

..... Co-Treasurer

Accounts

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION

REPORT AND ACCOUNTS

FOR THE YEAR ENDED

31ST MARCH 2022

REGISTERED CHARITY NO. 1065026

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION

CONTENTS

	<u>Page</u>
Trust Information	2
Independent Examiner's Report	3
Trustees Annual Report	4 - 9
Statement of Financial Activities	10
Statement of Assets and Liabilities	11

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION

TRUST INFORMATION

Registered Charity No. 1065026

Trustees Robert Duncombe
Emma Foreman
Seonaid McLachlan

Treasurer Dharmisha Chauhan

Independent Examiner Barry Fine

Address c/o Dharmisha Chauhan
39 Oakley Road, Luton, LU4 9PT

Bankers National Westminster Bank plc

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

I report on the Accounts of the Association for the year ended 31st March 2022 which are set out on pages 10 - 11.

Respective Responsibilities of the Trustees and Examiner

The charity's trustees are responsible for the preparation of the accounts.

The charity's trustees consider that an audit is not required for this year under section 144 of the Charities Act 2011 (the Charities Act) and that an independent examination is needed.

It is my responsibility to:

examine the accounts under section 145 of the Charities Act,

to follow the procedures laid down in the general directions given by the Charity Commission (under section 145(5)(b)) of the Charities Act, and

to state whether particular matters have come to my attention.

Basis of Independent Examiner's Report

My examination was carried out in accordance with the General Directions given by the Charity Commissioners. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the Accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

Independent Examiner's Statement

In connection with my examination, no matter has come to my attention.

- 1) which gives me reasonable cause to believe that in any material respect the requirements
 - a. to keep accounting records in accordance with Section 130 of the Charities Act, and
 - b. to prepare Accounts which accord with the accounting records and comply with the accounting requirements of the Charities Act.have not been met; or
- 2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the Accounts to be reached.

Name. B. Fine FCA
Address Parkgates
Bury New Road
Prestwich
Greater Manchester
M25 0JW

Signed.....
Dated.....

BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

BOPA is an unincorporated organisation governed by its constitution.

Charity Number 1065026

Administrative Details

Principal address: 39 Oakley Road, Luton, Bed, LU4 9PT

<u>Committee Members</u>	<u>Office</u>	<u>Dates acted if not whole year</u>
Emma Foreman	Co-Chair	Ending October 2022
Joseph Williams	Co-Chair	Started October 2021
Jessica Pealing	Secretary	Started October 2021
Dharmisha Chauhan	Co-Treasurer	Ending October 2022
James Clark	Co-Treasurer	Started October 2021
Colm Doody		Started October 2021
Nisha Shaunak		Started October 2021
Melanie Lowe		Ending October 2022
Clare Geoghegan		
Lynn Ansell		
Bastiaan Buijtenhuijs		
Shereen Nabhani-Gebara		
Rebecca Devine		
Seonaid McLachlan	Co-Chair	Ended October 2021
Richard Allen		Ended October 2021
Islam Elkonaissi		Ended October 2021
Alkesh Patel		Ended October 2021

Structure

Members of the committee are elected for a three year term of office by the voting members through an electronic ballot. Each candidate provides a written statement in support of their application. These statements are electronically submitted to the members. The results of the election are announced at the Annual Symposium. Members can serve a maximum of two consecutive terms of office on the committee.

This committee then votes for the officers of Chair and Treasurer between themselves.

The association does not require any fundraising or grant-making activities. It is self-funding by members subscriptions, with additional sponsorship from the pharmaceutical industry for key projects such as e-Learning.

Decisions are made at the monthly committee meetings on behalf of the membership. The committee have several sub committees which feed back to the committee their decisions and ideas on behalf of the membership.

Sub committees:

1. Annual Symposium
2. Education and Training
3. Audit and Research
4. Community Pharmacy
5. Digital
6. Guidelines, Advocacy and Publications
7. Pharmacy Technician
8. Workforce and Capacity

Governance

Due to the nature of this charity no policies are in place to recruit and train trustees. Generally, those people elected by the members of the association are then responsible for the maintenance and safe handling of the Charity on behalf of the members.

Any decisions that require the membership to be involved in, such as national consultation documents, the document is placed on the BOPA website and emailed throughout the membership for comments to be received by the reference sub-committee who will then collate the response and return it.

The association works closely with the NHS England Cancer Area Team Pharmacists, and other relevant (oncology) pharmacy groups.

Objectives

The stated aim of BOPA is to promote excellence in the pharmaceutical care of patients with cancer through education, communication, research and innovation by an alliance of hospital, community and academic pharmacists, pharmacy technicians, those in the pharmaceutical industry and other healthcare professionals.

Public Benefit

These activities are undertaken to further the charitable purposes for the public benefit and the trustees believe that these activities satisfy the charity commissions general guidance on public benefit.

Achievements and performance

In April 2021 we continued to work around COVID-19 restrictions however some of our events started to revert to its face-to-face format as restrictions started to lift over time. We were pleased to host our annual Introduction to Oncology Day as a face-to-face event bringing back some normality to our educational sessions. However, some events remained virtual, allowing people to access training in their comfort of their homes. To ensure a more strategic implementation of educational sessions for our members in partnership with MEC to develop electronic cancer modules which can be routinely updated as new developments within cancer treatments occurs. Additionally, with the Bone Marrow Transplant specialist interest group the educational sub-committee organised new bone marrow transplant learning modules.

The educational subcommittee have been developing ways to provide educational content in different ways and within this financial year podcasts have been developed with more on the way for the 2022-2023.

The annual BOPA symposium is our biggest face-to-face educational event of the year. However, it was not possible to continue with a face-to-face format due to the ongoing COVID-19 restrictions. Therefore, this event was held in October as a virtual event for all paid BOPA members. The event was well attended, and we continued to attract international participation. Overall, we were able to provide a high quality and educational conference, with the event being rated very positively by our members.

Building on the success of the launch of Let's Communicate Cancer developed from the Pfizer grant the community pharmacy subcommittee were able to obtain accreditation for the eLearning modules. This educational resource will enable community pharmacists to engage with cancer patients with confidence and enable them to further develop their skill set, developing a knowledge base around cancer and its treatments. Now accredited, the learning modules can be used as an official training resource.

The digital sub-committee team worked incredibly hard to engage with our BOPA members in a new hybrid world. The team increased social and media posts throughout the year, sharing educational resources and information, with increasing number of Twitter followers (3,047), over 1000 forum posts, sharing 161 job vacancies and 853 educational and training resources. The BOPA website continues to be updated to improve usability and functionality, for example all members can register for educational webinars via the website and view the recorded sessions if unable to attend the live session.

The research and audit sub-committee continue to host research webinars to ensure more pharmacy professionals engage and feel confident to conduct their own research projects, and to build upon this a new research mentor support programme has been created.

Despite the challenges faced during COVID-19, the BOPA committee found innovative ways to continue to engage with our members by continuing to offer high-quality educational and training resources throughout the year. Additionally, plans are now underway to host the next symposium as a face-to face event in Liverpool and to kick-start educational and research grants which were rolled over due to the COVID-19 restrictions.

Benefit to the public

As an organisation promoting excellence in the pharmaceutical care of patients with cancer, BOPA provides up-to-date resources for academic pharmacists, pharmacy technicians, those in the pharmaceutical industry and other healthcare professionals. Thereby promoting up-to-date safe and efficient practice through education, training and through participating in collaborative research both nationally and at a global level.

Activities undertaken to benefit the public

1. Let's Communicate Cancer project. The aim of the project is to educate and up-skill community pharmacists to engage with the public in the community setting with confidence and developing a knowledge base around cancer and its treatments.
2. Annual BOPA symposium: Providing educational sessions to our members, on areas such as clinical management in cancer, good practice research methods (e.g., engaging with patients, public and carers) and scientific updates. This ensures our members have the knowledge, skills, and confidence to manage and work with cancer patients at their place of work.

Financial review

- BOPA de-registered for VAT during 2020 following advice received from expert VAT advisors as all HMRC payments and rebates were made and BOPA is now back to a non-profit charitable organisation.

Trustees/members expenses for services

As a charitable organisation members and trustees are eligible for travel expenses, team building exercises and hotel accommodation. In this financial year the total cost is £3,377

In this financial year meetings were held both virtually and with one face-to-face event in December.

Reserve accounts

The Charity holds cash funds of £21,679 split between a Nat West Bank account and a Scottish Widows account of which £2,520 are restricted.

The reason for holding these reserves is:

1. In the event of a reduction in income the charity will be able to continue to provide its core functions and cover all existing fixed costs and commitments e.g., website maintenance.
2. The charity provides an annual educational event. In the normal course of events these meetings are at least “break even”. However, there is the risk that the income for this meeting may be below the costs associated with running the meeting, and BOPA will be liable for this shortfall.

Summary of accounts

The total income received was £71,991 and the total payments made were £71,596

This giving BOPA a surplus for the year of £395 and total assets/funds of £216,769 split between unrestricted of £214,249 and restricted funds of £2,520.

Plans for the future

1. To continue to collaborate with national and international (oncology) pharmacy groups to maintain and consolidate its professional and advocacy role.
2. During 2022-2023 BOPA will continue to develop and provide high quality education and training materials for all their members.
3. BOPA is also keen to develop educational scholarships for its members and to fund research into Pharmacy Practice Research where there is a focus on cancer.
4. The BOPA 2022 symposium will be delivered as a face-to-face in Liverpool.

Declaration

Signed on behalf of the charity’s trustees

Signature	
Full Name	Ms Emma Foreman
Position	Chair
Date	
Signature	
Full Name	Ms Seonaid McLachlan
Position	Chair
Date	
Signature	
Full Name	Mr Rob Duncombe
Position	BOPA Trustee
Date	

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION
Receipts and Payments Account 2021-2022

	Unrestricted	Restricted	Total	Total
	Funds 2022	Funds 2022	2022	2021
<u>Receipts</u>				
	£	£	£	£
Members Subscriptions	55,405		55,405	58,632
Interest Receivable	86	xx	86	70
Grants				0
Ipsen -Day in the life		7,500	7,500	
Oxford University -training		2,500	2,500	
Pfizer- Watson research		6,500	6,500	
Symposium/ISOPP attendance				2,035
Donation (surplus from Isopp)				10,988
GROSS INCOME	55,491	16,500	71,991	71,725
*.2020 Donation from Pfizer for the Community Pharmacy Education Project.				
<u>Payments</u>				
Executive Travel	759	0	759	435
Expenses	3,377		3,377	
ISOPP 2020		0		808
Digital	16,370	0	16,370	25,623
Data Protection Charge	0	0	0	0
Symposium Costs	18,484	0	18,484	36,050
Audit / Accountancy	,	0		1,200
Professional Indemnity Insurance	817	0	817	740
Study days	0	0	0	0
On-line banking	110	0	110	28
ISOPP HMRC Net VAT Expense		0		13,678
HMRC VAT Interest		0		843
Secretariat	0	0	0	0
Research Sage Publication	4,320	0	4,320	0
Community Pharmacy project		5,104	5,104	78,976
Advertising materials				169
Educational Audit				7,385

Donation				200
Educational	5,481		5,481.	
Day in the life	1,544	7,500	9,044.	
Pfizer Watson research		6,500	6,500	
Administration costs	1,230		1,230	
Merchandise	.			
TOTAL EXPENDITURE	52,492.	19,104.	71,596.	166,135
Net Surplus				
(Payments) - Receipts	£2,999	£(2,604)	£395	£(94,410)
Cash funds last year end	211,250	5,124	216,374	310,784
Cash funds this year end	£214,249	£2,520	£216,769	£216,374

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION		
STATEMENT OF ASSETS & LIABILITIES		
Current Assets	2021/22	2020/21
	£	£
Current Account	115,852	115,543
Business Reserve Account	18,489	18,487
Scottish Widows Deposit Account	82,428	82,344
	£216,769	£216,374
Creditors	0	
Current Liabilities	0	
Net Current Assets	£216,769	£216,374

The Accounts were approved by the Committee on

.....Chair

.....Chair

.....Treasurer

Accounts

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION

REPORT AND ACCOUNTS

FOR THE YEAR ENDED

31ST MARCH 2021

REGISTERED CHARITY NO. 1065026

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION

CONTENTS

	<u>Page</u>
Trust Information	2
Independent Examiner's Report	3
Trustees Annual Report	4 - 9
Statement of Financial Activities	10
Statement of Assets and Liabilities	11

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION

TRUST INFORMATION

Registered Charity No. 1065026

Trustees Robert Duncombe
Emma Foreman
Seonaid McLachlan

Treasurer Dharmisha Chauhan

Independent Examiner Barry Fine

Address c/o Dharmisha Chauhan
39 Oakley Road, Luton, LU4 9PT

Bankers National Westminster Bank plc

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

I report on the Accounts of the Association for the year ended 31st March 2021 which are set out on pages 10 - 11.

Respective Responsibilities of the Trustees and Examiner

The charity's trustees are responsible for the preparation of the accounts.

The charity's trustees consider that an audit is not required for this year under section 144 of the Charities Act 2011 (the Charities Act) and that an independent examination is needed.

It is my responsibility to:

examine the accounts under section 145 of the Charities Act,

to follow the procedures laid down in the general directions given by the Charity Commission (under section 145(5)(b)) of the Charities Act, and

to state whether particular matters have come to my attention.

Basis of Independent Examiner's Report

My examination was carried out in accordance with the General Directions given by the Charity Commissioners. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the Accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

Independent Examiner's Statement

In connection with my examination, no matter has come to my attention.

- 1) which gives me reasonable cause to believe that in any material respect the requirements
 - a. to keep accounting records in accordance with Section 130 of the Charities Act, and
 - b. to prepare Accounts which accord with the accounting records and comply with the accounting requirements of the Charities Act.have not been met; or
- 2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the Accounts to be reached.

Name. B. Fine FCA
Address Parkgates
Bury New Road
Prestwich
Greater Manchester
M25 0JW

Signed.....
Dated.....

BRITISH ONCOLOGY PHARMACY ASSOCIATION (BOPA)

BOPA is an unincorporated organisation governed by its constitution.

Charity Number 1065026

Administrative Details

Principal address: 39 Oakley Road, Luton, Bed, LU4 9PT

<u>Committee Members</u>	<u>Office</u>	<u>Dates acted if not whole year</u>
Emma Foreman	Co-Chair	
Seonaid McLachlan	Co-Chair	
Netty Cracknell	Secretary	Ended October 2020
Joseph Williams	Secretary	Started October 2020
Rob Duncombe	Treasurer	Ended October 2020
Dharmisha Chauhan	Treasurer	Started October 2020
Pinkie Chambers		
Richard Allen		
Islam Konaissi		
Alkesh Patel		
Melanie Lowe		
Clare Geoghegan		Started October 2020
Lynn Ansell		Started October 2020
Bastiaan Buijtenhuijs		Started October 2020
Shereen Nabhani-Gebara		Started October 2020
Rebecca Devine		Started October 2020
Emma Groves		Ended October 2020
Olga Crehan		Ended October 2020
Susanna Daniels		Ended October 2020

Structure

Members of the committee are elected for a three year term of office by the voting members through an electronic ballot. Each candidate provides a written statement in support of their application. These statements are electronically submitted to the members. The results of the election are announced at the Annual Symposium. Members can serve a maximum of two consecutive terms of office on the committee.

This committee then votes for the officers of Chair and Treasurer between themselves.

The association does not require any fundraising or grant-making activities. It is self-funding by members subscriptions, with additional sponsorship from the pharmaceutical industry for key projects such as e-Learning.

Decisions are made at the monthly committee meetings on behalf of the membership. The committee have several sub committees which feed back to the committee their decisions and ideas on behalf of the membership.

Sub committees:

1. Annual Symposium
2. Education and Training
3. Audit and Research
4. Community Pharmacy
5. Digital
6. Guidelines, Advocacy and Publications

Governance

Due to the nature of this charity no policies are in place to recruit and train trustees. Generally those people elected by the members of the association are then responsible for the maintenance and safe handling of the Charity on behalf of the members.

Any decisions that require the membership to be involved in, such as national consultation documents, the document is placed on the BOPA website and emailed throughout the membership for comments to be received by the reference sub-committee who will then collate the response and return it.

The association works closely with the NHS England Cancer Area Team Pharmacists, and other relevant (oncology) pharmacy groups.

Objectives

The stated aim of BOPA is to promote excellence in the pharmaceutical care of patients with cancer through education, communication, research and innovation by an alliance of hospital, community and academic pharmacists, pharmacy technicians, those in the pharmaceutical industry and other healthcare professionals.

Public Benefit

These activities are undertaken to further the charitable purposes for the public benefit and the trustees believe that these activities satisfy the charity commissions general guidance on public benefit.

Achievements and performance

In April 2020 we were in the peak of the COVID-19 pandemic and activities which we initially set out to do, changed. Focus was directed on how best to serve our members during an incredibly unprecedented and difficult time. Our members were faced with redeployment, increased clinical activities caring for COVID-19 patients and developing new services that had to be adapted to the government “stay at home” message, in addition to the anxieties and challenges presented at home e.g., home schooling. To support our members during this difficult and uncertain times, the committee agreed to provide free membership and access to the BOPA resources for 3 months. This was for both new and existing BOPA members. Resources on COVID-19 updates could be freely accessed during this time and members could also access the forums for clinical advice and support. Therefore, a reduction in membership fees can be seen between April to June/July 2020.

The BOPA committee adapted to the times by developing more webinar courses. For example, the Statistics Without Tears course, consisting of 6 modules, was well attended and hugely popular. Our regular Introduction to Oncology Day, normally a face-to-face event was presented to members virtually in the Summer of 2020, as we were determined not to disrupt our long-standing educational sessions. One of our highlights of the year was a collaborative webinar held in association with The Canadian Association of Pharmacy in Oncology (CaPhO) and the International Society of Oncology Pharmacy

Practitioners (ISOPP) presenting the evidence to support COVID vaccination in cancer patients and to share UK best practice guidelines with colleagues from around the world.

Other courses such as specialist haematology sessions were also provided virtually and we are pleased to say that members engaged positively and as more sessions were available via a live stream, more members were able to attend from the comfort of their home.

The annual BOPA symposium is our biggest face-to-face educational event of the year. However, it was not possible to continue with a face-to-face format due to the ongoing COVID-19 restrictions. This event was held 9-11th October virtually and for all paid BOPA members, the symposium was free to attend. The event was attended by over 800 members, and we attracted international participation. Overall, we were able to provide a high quality and educational conference, with the event be rated very positivity from our members.

The community pharmacy sub-committee continued to work tirelessly on a new educational resource for community pharmacists. A grant was obtained from Pfizer, a pharmaceutical company, and the project was fully underway in April 2020. Now completed, this new educational resource will enable community pharmacists to engage with cancer patients with confidence and enable them to further develop their skill set, in particular developing a knowledge base around cancer and its treatments.

BOPA continued to be an active member of the UK chemotherapy board and collaborated on key national documents e.g. The Management of Glycaemic Control in Patients with Cancer. BOPA supported several virtual conferences and meetings during 2020-2021, for example, the Clinical Pharmacy Congress and the Oncology Forum Conference.

Due to the COVID-19 pandemic a decision was made to roll over BOPA grants for research funding to the next financial year. However, we were able to launch national data collection research project to assess the hypersensitivity risk of anti-cancer chemotherapy regimen, with and without a commonly prescribed drug called ranitidine, which is used to prevent hypersensitivity reactions. In total 30 hospital Trusts signed up including some private hospitals, to help with data collection. An interim analysis has started and the results will be published in a peer-reviewed journal once completed.

The digital sub-committee team worked incredibly hard to engage with our BOPA members in a new virtual world. The virtual educational presentations were placed on our BOPA website for members for on-demand viewing.

Despite the challenges faced in 2020, the BOPA committee found innovative ways to continue to engage with our members, ensuring that we continued to offer high-quality educational and training resources throughout the year. Additionally, we were aware that paying for educational resources during a turbulent time would be challenging for our members and by providing 3 months free membership and a free virtual 2020 symposium was another way in which we were able to support our members.

Benefit to the public

As an organisation promoting excellence in the pharmaceutical care of patients with cancer, BOPA provides up-to-date resources for academic pharmacists, pharmacy technicians, those in the pharmaceutical industry and other healthcare professionals. Thereby promoting up-to-date safe and efficient practice through education, training and through participating in collaborative research both nationally and at a global level.

Activities undertaken to benefit the public

1. Let's Communicate Cancer project. The aim of the project is to educate and up-skill community pharmacists to engage with the public in the community setting with confidence and developing a knowledge base around cancer and its treatments.
2. The Management of Glycaemic Control in Patients with Cancer, a collaborative piece of work to ensure the public are prescribed with cancer treatment and have diabetes are managed safely.
3. Annual BOPA symposium: Providing educational sessions to our members, on areas such as clinical management in cancer, good practice research methods (e.g., engaging with patients, public and carers) and scientific updates. This ensures our members have the knowledge, skills, and confidence to manage and work with cancer patients at their place of work.

Financial review

- The association monies are provided and maintained by the membership subscription. However, to support our members during this difficult and uncertain times, the committee agreed to provide free membership and access to the BOPA resources for 3 months. This was for both new and existing BOPA members.
- BOPA de-registered for VAT during 2020 following advice received from expert VAT advisors as all HMRC payments and rebates were made and BOPA is now back to being a non-profit charitable organisation.
- With the surplus generated after the ISOPP 2019 conference we were able to provide all paid members free access to the BOPA 2020 virtual conference.

Trustees/members expenses for services

As a charitable organisation members and trustees are eligible for travel expenses, team building exercises and hotel accommodation. In this financial year the total cost is stated below:

Team building exercise at £434.72

In this financial year, no travel or hotel expenses were made, as all meetings were held virtually due to the government advice and regulations surrounding "stay at home" measures due to the COVID-19 pandemic. Therefore, to ensure the committee members had a chance to interact in a non-formal way, a team building exercise was held.

Grant – Let's Communicate Cancer

On the 24th of December 2019, BOPA received a restricted grant of £90,400 from Pfizer, a pharmaceutical company. This grant was provided to the community pharmacy sub-committee to produce educational on-line course for community pharmacists. The project was titled Let's Communicate Cancer. The aim of the project is to educate and up-skill community pharmacists to engage with cancer patients with confidence and developing a knowledge base around cancer and its treatments.

During this financial year £78,976 (2020 £6,300) was spent of the £90,400.

Reserve accounts

The Charity holds cash funds of £216,374 split between a Nat West Bank account and a Scottish Widows account of which £5,124 are restricted.

The reason for holding these reserves is:

1. In the event of a reduction in income the charity will be able to continue to provide its core functions and cover all existing fixed costs and commitments e.g., website maintenance.
2. The charity provides an annual educational event. In the normal course of events these meetings are at least “break even”. However, there is the risk that the income for this meeting may be below the costs associated with running the meeting, and BOPA will be liable for this shortfall.

Summary of accounts

The total income received was £71,725 and the total payments made were £166,135

This giving BOPA a deficit for the year of £94,410 and total assets/funds of £216,374 split between unrestricted of £211,250 and restricted funds of £5,124.

Plans for the future

1. To continue to collaborate with national and international (oncology) pharmacy groups to maintain and consolidate its professional and advocacy role.
2. During 2021-2022 BOPA will continue to develop and provide high quality education and training materials for all their members.
3. BOPA is also keen to develop educational scholarships for its members and to fund research into Pharmacy Practice Research where there is a focus on cancer.
4. The BOPA 2021 symposium will be delivered virtually, with the aim that the 2022 symposium will be held back to its original face-to-face format.

Declaration

Signed on behalf of the charity's trustees

Signature

Full Name Ms Emma Foreman

Position Chair

Date

Signature

Full Name Ms Seonaid McLachlan

Position Chair

Date

Signature

Full Name Mr Rob Duncombe

Position BOPA Trustee

Date

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION
Receipts and Payments Account 2020-2021

	Unrestricted	Restricted	Total	Total
	Funds 2021	Funds 2021	2021	2020
Receipts				
	£	£	£	£
Members Subscriptions	58,632		58,632	83,537
Interest Receivable	70	0	70	120
Grants	0	0*	0	102,020
Symposium/ISOPP attendance	2,035		2,035	600
Donation (surplus from Isopp)	10,988		10,988	69,302
GROSS INCOME	71,725	0	71,725	255,579
*.2020 Donation from Pfizer for the Community Pharmacy Education Project.				
Payments				
Executive Travel	4,35	0	435	4,206
ISOPP 2020	808	0	808	0
Digital	25,623	0	25,623	47,039
Data Protection Charge	0	0	0	35
Symposium Costs	36,050	0	36,050	0
Audit / Accountancy	1,200	0	1,200	3,780
Professional Indemnity Insurance	740	0	740	1,296
Study days	0	0	0	23,557
On-line banking	28	0	28	41
ISOPP HMRC Net VAT Expense	13,678	0	13,678	0
HMRC VAT Interest	843	0	843	0
Secretariat	0	0	0	18,000
Research Grants	0	0	0	7497
Community Pharmacy project		78,976	78,976	6,300
Advertising materials	169		169	3,277
Educational Audit	7,385		7,385	6,588
Donation	200		200	
TOTAL EXPENDITURE	87,159	78,976	166,135	121,616
Net Surplus				
(Payments) - Receipts	£(15,434)	£(78,976)	£(94,410)	£133,963
Cash funds last year end	226,684	84,100	310,784	176,821
Cash funds this year end	£211,250	£5,124	£216,374	£310,784

THE BRITISH ONCOLOGY PHARMACY ASSOCIATION		
STATEMENT OF ASSETS & LIABILITIES		
Current Assets	2020/21	2019/20
	£	£
Current Account	115,543	210,023
Business Reserve Account	18,487	18,479
Scottish Widows Deposit Account	82,344	82,282
	£216,374	£310,784
Creditors	0	
Current Liabilities	0	
Net Current Assets	£216,374	£310,784

The Accounts were approved by the Committee on

.....Chair

.....Chair

.....Treasurer